Introduction Antiretroviral medication coverage remains sub-optimal in much of the United
States, particularly the Sothern region, and Non-Hispanic Black or African American persons …

Background: Significant racial disparities exist in HIV pre-exposure prophylaxis (PrEP)
coverage in the United States (US), with Black individuals experiencing seven times higher …

While remarkable progress has been achieved in HIV treatment and prevention over the
past decade through widespread access to and use of antiretrovirals, HIV incidence has yet …

Human immunodeficiency virus (HIV) is a major public health concern in the United States,
with about 1.2 million people living with HIV and 35,000 newly infected each year. There are …

Background The degree to which the 2019 novel coronavirus disease (COVID-19)
pandemic will affect the US human immunodeficiency virus (HIV) epidemic is unclear …

Background The “Ending the HIV Epidemic”(EHE) initiative seeks to reduce new HIV
infections in the US by prioritizing federal resources towards highly impacted populations …

Background: Pre-exposure prophylaxis (PrEP) is a key component in helping to reduce HIV
incidence in the United States. Long-acting injectable (LAI) PrEP is a new alternative to oral …

Background US progress toward ending the HIV epidemic was disrupted during the COVID‐
19 pandemic. Objectives To determine the impact of the pandemic on HIV‐related mortality …

Introduction Mathematical models of HIV have been uniquely important in directing and
evaluating HIV policy. Transgender and nonbinary people are disproportionately impacted …

Summary Background The US Ending the HIV Epidemic (EHE) initiative aims to reduce
national HIV incidence 90% by 2030 and to address the disproportionate burden of HIV …